We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Breast Cancer: LONG-TERM TAMOXIFEN IN ER+ BREAST CANCER.
- Authors
Grenier, Debjani
- Abstract
The article discusses the long-term effect of adjuvant tamoxifen in estrogen receptor (ER)-positive early breast cancer. The Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) trial aimed to assess the further effects of continuing tamoxifen to 10 years instead of stopping at five years. Furthermore, the treatment with tamoxifen for women with ER-positive early breast cancer for five years substantially reduces the breast cancer mortality rate throughout the first 15 years after diagnosis.
- Subjects
CLINICAL trials; BREAST cancer treatment; TAMOXIFEN; ESTROGEN receptors; TREATMENT effectiveness; DRUG efficacy
- Publication
Oncology Exchange, 2013, Vol 12, Issue 1, p36
- ISSN
1705-2394
- Publication type
Article